| [1] |
Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Med J Australia, 18 69, 14: 146-7.
|
| [2] |
Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J]. J Clin Oncol, 2007, 25(33): 5287-312.
|
| [3] |
Lianidou ES, Mavroudis D, Georgoulias V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer[J]. Br J Cancer, 2013, 108(12): 2426-32.
|
| [4] |
Lianidou ES, Markou A, Strati A. Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment[J]. Cancer Metastasis Rev, 20 12, 31(3-4): 663-71.
|
| [5] |
van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk non-muscle-invasive bladder cancer and tumour progression: a systematic review[J]. Eur Urol, 20 11, 60(3): 493-500.
|
| [6] |
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M]. 7th edition. New York: Springer, 2010: 347-76.
|
| [7] |
Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients[J]. Cancer Cell, 20 13, 23(5): 573-81.
|
| [8] |
Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?[J]. Carcinogenesis, 2006, 27(3): 361-73.
|
| [9] |
Sylvester RJ. How well can you actually predict which non-muscleinvasive bladder cancer patients will progress?[J]. Eur Urol, 2011, 60 (3): 431-3.
|
| [10] |
Rink M, Chun FK, Minner S, et al. Detection of circulating tumor cells in peripheral blood of patients with advanced non-metastatic bladder cancer[J]. BJU Int, 2011, 107(10): 1668-75.
|
| [11] |
Gradilone A, Petracca A, Nicolazzo C, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer[J]. BJU Int, 2010, 106(5): 710-5.
|
| [12] |
Gazzaniga P, Raimondi C, Gradilone A, et al. Circulating tumor cells: highlight on practical implications[J]. Mol Diagn Ther, 20 12, 16(1): 7-11.
|
| [13] |
Tomasini JM, Konety BR. Urinary markers/cytology: what and when should a urologist use[J]. Urol Clin North Am, 2013, 40(2): 16 5-73.
|
| [14] |
Flaig TW, Wilson S, van Bokhoven A, et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma[J]. Urology, 2011, 78(4): 863-7.
|
| [15] |
Gallagher DJ, Milowsky MI, Ishill N, et al. Detection of circulating tumor cells inpatients with urothelial cancer[J]. Ann Oncol, 2009, 20(2): 305-8.
|
| [16] |
Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study[J]. Eur Urol, 2012, 61(4): 810-7.
|
| [17] |
Youssef RF, Lotan Y. Predictors of outcome of non-muscleinvasive and muscle-invasive bladder cancer[J]. Sci World J, 20 11, 11: 369-81.
|
| [18] |
Gazzaniga P, Gradilone A, de Berardinis E, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis[J]. Ann Oncol, 2012, 23(9): 2352-6.
|
| [19] |
Gazzaniga P, de Berardinis E, Raimondi C, et al. Circulating tumor cells detection has independent prognostic impact in high-risk nonmuscle invasive bladder cancer[J]. Int J Cancer, 2014, 135(8): 1978-82.
|
| [20] |
Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials[J]. Eur Urol, 2014, 66(1): 42-54.
|
| [21] |
Gore JL, Gilbert SM. Improving bladder cancer patient care: a pharmacoeconomic perspective[J]. Expert Rev Anticancer Ther, 20 13, 13(6): 661-8.
|
下载:
